Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992 May;17(5):489-95.
doi: 10.1007/BF00969897.

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

Affiliations
Comparative Study

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

N Ogane et al. Neurochem Res. 1992 May.

Abstract

The effect of eight different acetylcholinesterase inhibitors (AChEIs) on the activity of acetylcholinesterase (AChE) molecular forms was investigated. Aqueous-soluble and detergent-soluble AChE molecular forms were separated from rat brain homogenate by sucrose density sedimentation. The bulk of soluble AChE corresponds to globular tetrameric (G4), and monomeric (G1) forms. Heptylphysostigmine (HEP) and diisopropylfluorophosphate were more selective for the G1 than for the G4 form in aqueous-soluble extract. Neostigmine showed slightly more selectivity for the G1 form both in aqueous- and detergent-soluble extracts. Other drugs such as physostigmine, echothiophate, BW284C51, tetrahydroaminoacridine, and metrifonate inhibited both aqueous- and detergent-soluble AChE molecular forms with similar potency. Inhibition of aqueous-soluble AChE by HEP was highly competitive with Triton X-100 in a gradient, indicating that HEP may bind to a detergent-sensitive non-catalytic site of AChE. These results suggest a differential sensitivity among AChE molecular forms to inhibition by drugs through an allosteric mechanism. The application of these properties in developing AChEIs for treatment of Alzheimer disease is considered.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mol Pharmacol. 1966 Sep;2(5):369-92 - PubMed
    1. J Biol Chem. 1987 Apr 5;262(10):4441-4 - PubMed
    1. Neurochem Res. 1990 Oct;15(10):975-9 - PubMed
    1. J Neurosci. 1981 Nov;1(11):1260-7 - PubMed
    1. Biol Psychiatry. 1990 Mar 15;27(6):573-80 - PubMed

Publication types

MeSH terms